Strategic Management to Optimize Response To Cardiac Resynchronization Therapy

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 699 participants.

Also called NCT03089281

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 699 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03089281
Other papers using this trial's data
  • Effects of Atrioventricular Optimization on Left Ventricular Reverse Remodeling With Cardiac Resynchronization Therapy: Results of the SMART-CRT Trial Circulation. Arrhythmia and electrophysiology, 2023-06 DOI, PubMed 37183700

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada, France, Germany, Ireland, Italy, Japan, Netherlands, Spain, Switzerland, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03089281. Randomized; double masking; primary purpose treatment. Start 2017-08-01 (actual); primary completion 2020-09-15 (actual). Results posted on 2022-04-05.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Strategic Management to Optimize Response To Cardiac Resynchronization Therapy
Acronym
SMART CRT
Condition
Heart Failure
Intervention (Device)
CRT-D
Lead sponsor
Boston Scientific Corporation (class: industry)

Record details

Record id
cardio:ct-nct03089281
Content hash
edc298d419e7f1a5fd2c97f7a4a5457d77a44bec60f9fd5794f75b7ef6bd41d2